FujiFilm

Ripcord, Inc. is a robotic digitization company that specializes in automating the management of paper records. Founded in 2014 and headquartered in Los Angeles, California, Ripcord develops a platform that utilizes advanced technologies, including artificial intelligence, machine learning, and vision-guided robotics, to create digital twins of physical documents. Its flagship solution, Canopy, captures, enriches, and organizes critical content, allowing enterprises to enhance their business processes with improved speed, quality, and accuracy. Formerly known as Ripcord Digital, Inc., the company rebranded in June 2017 to reflect its focus on innovative digitization solutions.

Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

MicroChannel Services is a multi-award-winning provider of business solutions and technology, established in 1995. The company serves mid-sized businesses, corporate divisions, and government agencies, assisting them in leveraging technology for improved commercial success. MicroChannel offers a range of services including customer relationship management, marketing technology, enterprise resource planning, warehouse management, and retail management. In addition, the company provides managed IT services and comprehensive business consultancy, enabling clients to enhance productivity, drive growth, and improve competitiveness in their respective markets. With a focus on delivering end-to-end operational and back-office systems, MicroChannel has successfully supported hundreds of clients in achieving their business objectives.

Inspirata, Inc. is an oncology informatics company dedicated to enhancing the cancer care experience for patients and clinicians. The firm provides innovative software solutions that utilize advanced artificial intelligence and natural language processing to streamline clinical trials and cancer registry operations. With over two decades of collaboration with the National Cancer Institute, Inspirata's proprietary AI and NLP engine powers key products such as Trial Navigator, which automates clinical trial matching, and E-Path Plus, a leading solution for cancer registry reporting and data abstraction. These tools are used by numerous healthcare institutions worldwide, aiming to improve patient outcomes and support healthcare professionals in their fight against cancer.

24M Technologies specializes in the development of energy storage systems for both grid and transportation applications. The company focuses on manufacturing lithium-ion batteries that enhance the operational reliability, economics, and efficiency of electric power systems. Its innovative approach features binder-free semisolid electrodes and unit cells, which not only improve battery performance but also eliminate the need for traditional hydro or pyrometallurgical processes in battery recycling. Additionally, 24M facilitates direct in-plant reuse of active materials at the end of a battery's life, contributing to more sustainable recycling practices and enabling clients to increase efficiency and reduce costs.

Cuorips Inc. is a medical care company based in Chuo, Japan, with an additional office in Osaka. Founded in 2017, the company focuses on the research, development, and commercialization of iPS cell-derived cardiomyocyte sheets and various cell therapeutic products. Cuorips is involved in the manufacturing and sales of cellular and tissue-based products, as well as providing contract development and manufacturing services. The company aims to advance medical treatments through innovative cell products and therapies.

Rege Nephro Co., Ltd., established in 2019 and based in Kyoto, Japan, is a biotech company focused on the research, development, production, and marketing of therapeutics for renal diseases. The company leverages induced pluripotent stem cell (iPSC) technology, sourced from the Center for iPS Cell Research and Application at Kyoto University, to create innovative treatments for kidney, liver, and pancreas conditions. Rege Nephro develops drugs that utilize core seeds technology, which includes pluripotent stem cells capable of producing erythropoietin (EPO) and specific nephron progenitor cell markers. This approach aims to minimize the reliance on dialysis among patients with renal failure by offering effective therapeutic alternatives. Additionally, the company produces kidney organoids designed for nephrotoxicity screening, facilitating drug discovery in applied research.

Nanox Imaging is a Gibraltar-based company founded in 2011 that specializes in advanced imaging technology for medical, security, and telecommunications applications. The company is pioneering next-generation X-ray emitters utilizing innovative nanotechnology to modernize X-ray imaging, enabling the development of novel 3D imaging systems with superior performance. Central to Nanox's offerings is the Nanox System, which provides a preventative healthcare service known as Medical Screening As A Service (MSaaS). The company has leveraged over two decades of research and development, investing more than $1 billion to create proprietary cold cathode technology that enhances X-ray imaging capabilities. This technology features a chip composed of nano-scale structures, designed through unique nanofabrication techniques, which supports various medical imaging applications and is complemented by additional technologies to maximize its practical benefits in real-world scenarios.

Lunit Inc. is a medical AI software company based in Seoul, South Korea, specializing in advanced algorithms for medical image analysis and general object detection. The company focuses on developing solutions that aid physicians in making objective diagnoses through machine learning technology. Lunit's expertise encompasses various medical imaging fields, including digital chest X-ray, digital mammography, digital pathology, and fundus photography. The company's products include Lunit INSIGHT CXR for chest X-rays, Lunit INSIGHT MMG for mammography, and Lunit SCOPE, which provides AI-powered biomarkers for immuno-oncology. Lunit aims to enhance clinical decision-making by leveraging data-driven imaging biomarker technology, ultimately improving the accuracy and efficiency of cancer care. The effectiveness of Lunit's deep learning technology has been validated through its recognition in major image recognition competitions, showcasing its capacity to process complex medical imaging data.

Fuji Xerox New Zealand is part of a global enterprise group that specializes in business and document management services. The company offers a comprehensive suite of technologies and solutions, including digital printing, document management, and business process outsourcing. By helping businesses reduce printing costs, streamline processes, and automate tasks, Fuji Xerox New Zealand aims to enhance operational efficiency and drive cost savings. The organization is committed to fostering long-term relationships with its clients and communities, and it actively supports various environmental, educational, and sporting initiatives. Through its scalable and cost-effective solutions, Fuji Xerox New Zealand seeks to empower local businesses to grow and transform.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

PuREC is a biotechnology company focused on developing culture technology to enhance the efficacy of medical treatments. The company's innovative approach involves rapidly evolving cell therapies and mesenchymal stem cell therapies. PuREC's technology is particularly applied in two critical areas: addressing hypophosphatasia, a rare bone-formation deficiency in newborns, and treating spinal canal stenosis, which is caused by disc herniation in the spine. By leveraging advanced therapeutic techniques, PuREC aims to empower clients in their fight against various diseases and contribute to advancements in transplantation medicine.

Junten Bio is focused on the research and development of cell-based therapies utilizing regenerative medicine technology. The company aims to enhance medical treatment options by investigating the mechanisms of immune rejection in vivo. Through its work, Junten Bio develops innovative cellular solutions that address the side effects associated with the use of immunosuppressive agents following organ transplantation. By improving patient outcomes and quality of life, the company seeks to reduce overall medical expenses related to transplant procedures.

LPixel Inc. specializes in developing advanced image analysis software solutions for life science research. Established in 2014 as a spin-out from the University of Tokyo, the company offers a range of products, including LPixel ImageJ Plugins, which assist researchers in analyzing life science images, and LP-exam, a tool designed to detect image manipulations and plagiarism. Additionally, LPixel provides IMACEL, a cloud-based image analysis system that utilizes artificial intelligence to perform morphological analysis, calculate cell counts, and classify images automatically. The company also focuses on creating software solutions to support cancer diagnoses and offers educational programs for researchers and students in the life sciences field. Based in Tokyo, LPixel is committed to enhancing research efficiency through innovative technology.

Suono Bio, Inc. is a biotechnology company based in Medford, Massachusetts, focused on developing innovative therapeutic products utilizing its proprietary delivery technology. Founded in 2016, the company specializes in the ultra-rapid, localized delivery of small molecules, biologics, nucleic acids, and gene therapies directly to the gastrointestinal tract, eliminating the need for encapsulation. Suono Bio aims to transform the treatment of challenging diseases, particularly those involving inflammatory-mediated conditions, by enabling efficient and effective delivery of therapeutics across various tissues. This technology has the potential to enhance patient recovery from gastrointestinal diseases by ensuring that treatments reach their intended targets quickly and effectively.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery and advanced antibody technology. Founded in 2001, the company specializes in antibody discovery, engineering, and target discovery, along with functional protein expression. Its services include mouse hybridoma sequencing, recombinant protein production, and contract research support for antibody development. Perseus Proteomics is dedicated to creating innovative antibody products and new medicines to improve healthcare outcomes for patients globally.

IS Japan, founded in 1989, manufactures in vitro fertilization products, products for cell culture, and products for research on regenerative medicine and cell therapy, and distributes Irvine Scientific's products in and outside Japan.

Xerox is a global technology company specializing in document management and printing solutions. It offers a wide range of products and services, including printing systems, digital presses, multifunction devices, and related software. Xerox also provides consulting, outsourcing, and managed print services to businesses, helping them optimize their document workflows and IT infrastructure. The company operates primarily in the U.S. (60% of revenue) and internationally (40%).

EdiGENE Japan, now known as Modalis Therapeutics Corporation, is an emerging biotechnology company based in Tokyo, Japan. Founded in 2016, it specializes in the research and development of innovative therapeutics aimed at addressing serious genetic disorders. The company utilizes its proprietary CRISPR-GNDM technology, which allows for locus-specific modulation of gene expression and histone modification without the necessity for double-stranded DNA cleavage or traditional gene editing techniques. Modalis Therapeutics has established a solid intellectual property foundation, including licenses from the University of Tokyo, to support its focus on developing treatments for orphan genetic diseases and other unmet medical needs.

EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.

Cyfuse Biomedical K.K. is a biotechnology company based in Tokyo, Japan, that specializes in the research, development, and commercialization of tissue fabrication systems and cell-based products. Founded in 2010, the company offers 3D BioFabrication systems that utilize robotic technology to assemble spheroids into customized 3D shapes, providing innovative solutions for cell delivery in research and therapeutic applications. Cyfuse develops and licenses 3D tissue products for therapeutic use and engages in contract manufacturing for research purposes. The applications of its products include blood vessel grafts for hemodialysis access and coronary artery bypass grafts, cardiac grafts for drug toxicology and myocardial infarction therapy, cartilage grafts for surgical reconstruction, and hepatocyte grafts for drug metabolism studies and hemophilia treatment. Cyfuse Biomedical serves various research and development institutes, including universities, and has established a strategic partnership with Shibuya Kogyo Co., Ltd.

Tokiwa Bio Inc. is a Japanese company based in Tsukuba that specializes in the development and manufacturing of drugs for regenerative medicine, particularly focusing on gene therapy. Founded in 2014, the company utilizes artificially synthesized vectors to introduce multiple genes into the cytoplasm of cells without causing damage to the existing genetic material. This innovative approach facilitates the creation of gene therapy drugs aimed at treating rare diseases, including hemophilia and ischemia. In addition to its gene therapy efforts, Tokiwa Bio also produces biopharmaceuticals, antibody drugs, and research reagents, positioning itself as a key player in the biopharmaceutical industry.

BONAC Corporation focuses on the research, development, manufacturing, and commercialization of nucleic acid pharmaceutical products, utilizing advanced nucleic acid platform technology. Established in 2010 and headquartered in Kurume, Japan, with an office in Tokyo, the company specializes in the production and sale of nucleic acid ingredients. BONAC offers a comprehensive suite of services that includes drug substance manufacturing and support for drug development, aiming to facilitate access to innovative drug substances for pharmaceutical and cosmetic manufacturers. Through its efforts, BONAC addresses unmet medical needs by advancing RNA technology and developing effective nucleic acid medicines.

RegCell is focused on developing innovative therapies for autoimmune diseases and cancer by enhancing or regulating the immune system. The company specializes in creating cell therapies that aim to address significant unmet medical needs. By returning regulatory T cells to the patient and activating them in vitro, RegCell seeks to provide effective treatment options for individuals suffering from these challenging conditions. Through its novel approach, the company aims to improve patient outcomes and address the complexities associated with autoimmune disorders and cancer.

Cynata Therapeutics Limited is an Australian company focused on developing and commercializing its proprietary Cymerus™ mesenchymal stem cell technology for therapeutic applications. The company’s lead product candidate, CYP-001, has completed Phase I clinical trials aimed at treating graft versus host disease. In addition to this, Cynata is exploring treatments for various conditions such as asthma, heart attack, diabetic wounds, coronary artery disease, and acute respiratory distress syndrome, among others, which are currently in preclinical stages. The Cymerus technology utilizes induced pluripotent stem cells (iPSCs) derived from adult donors, enabling the efficient and scalable production of mesenchymal stem cells. This innovative approach addresses existing limitations in stem cell manufacturing, allowing for virtually limitless quantities of therapeutic cells without the need for continuous donor sourcing. Cynata collaborates with several prestigious institutions, including Monash University and Massachusetts General Hospital, to advance its research and development efforts. Founded in 2011 and based in Carlton, Australia, Cynata is positioned to significantly contribute to the field of regenerative medicine.

Ultra Pure Solutions, Inc. is one of the largest manufacturers of high purity chemicals in North America.

FUJIFILM TeraMedica, Inc., based in Milwaukee, WI, is a leading global healthcare informatics company specializing in vendor-neutral, enterprise-wide solutions for medical image management. Founded in 2001, the company gained recognition for deploying the first patient-centric clinical image archive at the Mayo Clinic in 2003. TeraMedica's software has since been implemented in over 600 locations worldwide, demonstrating its capacity to adapt to diverse healthcare environments. The company's focus on customer satisfaction is supported by a robust technology platform designed for flexibility and integration within healthcare enterprises.

Cellular Dynamics International Inc., (CDI) is a developer and manufacturer of fully functioning cells in industrial quantities to precise specifications. CDI's proprietary products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell Products). CDI's products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use our products, among other purposes, for drug discovery and screening, to test the safety and efficacy of their small molecule and biological drug candidates, for stem cell banking, and in the research and development of cellular therapeutics.

SonoSite, Inc. is a leading provider of hand-carried ultrasound systems, specializing in the portable ultrasound market. The company has revolutionized diagnostic imaging by developing systems that deliver high-quality performance traditionally found in larger, expensive machines but in a compact, laptop-sized format. This innovation allows for enhanced efficiency in existing clinical settings and introduces new point-of-care applications in areas where ultrasound was previously impractical due to size or cost. SonoSite's products cater to various medical fields, including radiology, cardiology, obstetrics and gynecology, emergency medicine, and critical care. With over 40,000 systems sold since its inception in 1999, the company is recognized for its exceptional imaging performance, user-friendly design, and durability, ultimately contributing to safer and more affordable healthcare delivery in hospitals and clinical environments.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery and advanced antibody technology. Founded in 2001, the company specializes in antibody discovery, engineering, and target discovery, along with functional protein expression. Its services include mouse hybridoma sequencing, recombinant protein production, and contract research support for antibody development. Perseus Proteomics is dedicated to creating innovative antibody products and new medicines to improve healthcare outcomes for patients globally.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery and advanced antibody technology. Founded in 2001, the company specializes in antibody discovery, engineering, and target discovery, along with functional protein expression. Its services include mouse hybridoma sequencing, recombinant protein production, and contract research support for antibody development. Perseus Proteomics is dedicated to creating innovative antibody products and new medicines to improve healthcare outcomes for patients globally.

Dimatix is a world leader in the research, development, manufacture and sale of printheads used in industrial inkjet printers, which are increasingly being used in such fields as outdoor advertising and packaging materials. As such, the company supplies printheads and provides after-sales service to printer manufacturers and various other users. Using MEMS1, Dimatix has developed advanced piezoelectric printheads2 that feature superior quality and excellent durability.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery and advanced antibody technology. Founded in 2001, the company specializes in antibody discovery, engineering, and target discovery, along with functional protein expression. Its services include mouse hybridoma sequencing, recombinant protein production, and contract research support for antibody development. Perseus Proteomics is dedicated to creating innovative antibody products and new medicines to improve healthcare outcomes for patients globally.

Sericol is a global corporation engaged in the development, manufacturing and sale of inks for screen and package printing as well as industrial inkjet inks and materials. With inks for screen printing and wide format digital UV inkjet inks, the company maintains a leading market share position worldwide.